&nbsp;

Drugs Used:

palbociclib,

letrozole

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

LETRRIBO

Cancer Type:

Breast

Intent: Palliative

Funding:

Exceptional Access Program

ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria

ODB - General Benefit

letrozole

Drugs Used:

letrozole,

ribociclib

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

LORL

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.

Drugs Used:

lorlatinib

Quick Link(s):

Regimen Monograph

Feb 2025

Drug

lorlatinib

Other Name(s): Lorbrena®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Feb 2025

Regimen

LUSP

Cancer Type:

Hematologic,

Myelodysplastic Syndrome (MDS)

Intent: Palliative

Funding:

Exceptional Access Program

luspatercept - For the treatment of red-blood cell (RBC) transfusion-dependent anemia associated with Myelodysplastic Syndromes (MDS), according to clinical criteria

Drugs Used:

luspatercept

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Mesothelioma (Pleural),

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Drugs Used:

larotrectinib